Target Information

Target General Information

Top

Target ID

T42157 (Former ID: TTDI03382)

Target Name

SPS1/STE20-related protein kinase YSK4 (YSK4)

Synonyms

Regulated in COPD, protein kinase; RCK; Mitogen-activated protein kinase kinase kinase 19

Click to Show/Hide

Gene Name

MAP3K19

Target Type

Patented-recorded target

[1]

Disease

[+] 1 Target-related Diseases

Breast cancer [ICD-11: 2C60-2C6Y]

Function

Protein serine/threonine kinase activity, activation of protein kinase activity, signal transduction by protein phosphorylation, stress-activated protein kinase signaling cascade.

Click to Show/Hide

BioChemical Class

Kinase

UniProt ID

M3K19_HUMAN

EC Number

EC 2.7.11.1

Sequence

MSSMPKPERHAESLLDICHDTNSSPTDLMTVTKNQNIILQSISRSEEFDQDGDCSHSTLV
NEEEDPSGGRQDWQPRTEGVEITVTFPRDVSPPQEMSQEDLKEKNLINSSLQEWAQAHAV
SHPNEIETVELRKKKLTMRPLVLQKEESSRELCNVNLGFLLPRSCLELNISKSVTREDAP
HFLKEQQRKSEEFSTSHMKYSGRSIKFLLPPLSLLPTRSGVLTIPQNHKFPKEKERNIPS
LTSFVPKLSVSVRQSDELSPSNEPPGALVKSLMDPTLRSSDGFIWSRNMCSFPKTNHHRQ
CLEKEENWKSKEIEECNKIEITHFEKGQSLVSFENLKEGNIPAVREEDIDCHGSKTRKPE
EENSQYLSSRKNESSVAKNYEQDPEIVCTIPSKFQETQHSEITPSQDEEMRNNKAASKRV
SLHKNEAMEPNNILEECTVLKSLSSVVFDDPIDKLPEGCSSMETNIKISIAERAKPEMSR
MVPLIHITFPVDGSPKEPVIAKPSLQTRKGTIHNNHSVNIPVHQENDKHKMNSHRSKLDS
KTKTSKKTPQNFVISTEGPIKPTMHKTSIKTQIFPALGLVDPRPWQLPRFQKKMPQIAKK
QSTHRTQKPKKQSFPCICKNPGTQKSCVPLSVQPTEPRLNYLDLKYSDMFKEINSTANGP
GIYEMFGTPVYCHVRETERDENTYYREICSAPSGRRITNKCRSSHSERKSNIRTRLSQKK
THMKCPKTSFGIKQEHKVLISKEKSSKAVHSNLHDIENGDGISEPDWQIKSSGNEFLSSK
DEIHPMNLAQTPEQSMKQNEFPPVSDLSIVEEVSMEESTGDRDISNNQILTTSLRDLQEL
EELHHQIPFIPSEDSWAVPSEKNSNKYVQQEKQNTASLSKVNASRILTNDLEFDSVSDHS
KTLTNFSFQAKQESASSQTYQYWVHYLDHDSLANKSITYQMFGKTLSGTNSISQEIMDSV
NNEELTDELLGCLAAELLALDEKDNNSCQKMANETDPENLNLVLRWRGSTPKEMGRETTK
VKIQRHSSGLRIYDREEKFLISNEKKIFSENSLKSEEPILWTKGEILGKGAYGTVYCGLT
SQGQLIAVKQVALDTSNKLAAEKEYRKLQEEVDLLKALKHVNIVAYLGTCLQENTVSIFM
EFVPGGSISSIINRFGPLPEMVFCKYTKQILQGVAYLHENCVVHRDIKGNNVMLMPTGII
KLIDFGCARRLAWAGLNGTHSDMLKSMHGTPYWMAPEVINESGYGRKSDIWSIGCTVFEM
ATGKPPLASMDRMAAMFYIGAHRGLMPPLPDHFSENAADFVRMCLTRDQHERPSALQLLK
HSFLERSH

Click to Show/Hide

3D Structure

Click to Show 3D Structure of This Target

AlphaFold

Drugs and Modes of Action

Top

Clinical Trial Drug(s)

[+] 1 Clinical Trial Drugs

Quinazoline derivative 9

Drug Info

Phase 1

Breast cancer

[2]

Mode of Action

[+] 1 Modes of Action

Inhibitor

[+] 1 Inhibitor drugs

Quinazoline derivative 9

Drug Info

[1]

Cell-based Target Expression Variations

Top

Cell-based Target Expression Variations

Cell-based Target Expression Variations Info

Different Human System Profiles of Target	Top
Human Similarity Proteins of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target. A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs (Brief Bioinform, 21: 649-662, 2020). Human Similarity Proteins

Different Human System Profiles of Target

Top

Human Similarity Proteins of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.

A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs (Brief Bioinform, 21: 649-662, 2020).

Human Similarity Proteins

Protein Name	Pfam ID	Percentage of Identity (%)	E value
Mixed lineage kinase 3 (MAP3K11)	PF07714 ; PF14604	32.714 (88/269)	1.66E-35
Mixed lineage kinase 2 (MAP3K10)	PF07714 ; PF14604	32.210 (86/267)	5.34E-34
Mixed lineage kinase 4 (MAP3K21)	PF07714 ; PF14604	31.560 (89/282)	1.54E-33
Mitogen-activated protein kinase kinase kinase 12 (MAP3K12)	PF07714	30.469 (78/256)	9.16E-31
TGF-beta-activated kinase 1 (MAP3K7)	PF07714	31.203 (83/266)	1.42E-30
Mitogen-activated protein kinase kinase kinase 13 (MAP3K13)	PF07714	29.572 (76/257)	1.40E-28
Serine/threonine-protein kinase B-raf (BRAF)	PF00130 ; PF07714 ; PF02196 More >>	28.731 (77/268)	2.45E-25
Proto-oncogene c-Fer (FER)	PF00611 ; PF07714 ; PF00017 More >>	29.889 (81/271)	1.58E-24
Proto-oncogene c-RAF (c-RAF)	PF00130 ; PF07714 ; PF02196 More >>	27.526 (79/287)	2.33E-23
Proto-oncogene c-Fes (FES)	PF07714 ; PF00017	27.626 (71/257)	6.04E-23
MLK-related kinase (MLTK)	PF07714 ; PF00536	27.419 (68/248)	3.50E-22
Tyrosine-protein kinase Lyn (JTK8)	PF07714 ; PF00017 ; PF00018 More >>	27.344 (70/256)	5.27E-22
LIM domain kinase-2 (LIMK-2)	PF00412 ; PF00595 ; PF07714 More >>	25.943 (55/212)	7.00E-22
TYK2 tyrosine kinase (TYK2)	PF18379 ; PF18377 ; PF17887 ; PF07714 More >>	30.732 (63/205)	8.11E-22
Serine/threonine-protein kinase A-Raf (ARAF)	PF00130 ; PF07714 ; PF02196 More >>	27.974 (87/311)	1.61E-21
Tyrosine-protein kinase BRK (PTK6)	PF07714 ; PF00017 ; PF00018 More >>	28.063 (71/253)	3.40E-21
Janus kinase 2 (JAK-2)	PF18379 ; PF18377 ; PF17887 ; PF07714 ; PF00017 More >>	28.959 (64/221)	9.81E-21
Tyrosine-protein kinase ABL2 (ABL2)	PF08919 ; PF07714 ; PF00017 ; PF00018 More >>	26.667 (68/255)	2.35E-20
Tyrosine-protein kinase Tec (PSCTK4)	PF00779 ; PF00169 ; PF07714 ; PF00017 ; PF00018 More >>	26.923 (70/260)	2.51E-20
LIM domain kinase-1 (LIMK-1)	PF00412 ; PF00595 ; PF07714 More >>	28.169 (60/213)	3.21E-20
Renal carcinoma antigen NY-REN-64 (IRAK-4)	PF07714	30.233 (65/215)	3.35E-20
T-cell-specific kinase (ITK)	PF00779 ; PF00169 ; PF07714 ; PF00017 ; PF00018 More >>	26.641 (69/259)	7.77E-20
Kinase suppressor of Ras 2 (KSR2)	PF07714 ; PF13543 ; PF20406 More >>	23.792 (64/269)	1.27E-19
Tyrosine-protein kinase ABL1 (ABL)	PF08919 ; PF07714 ; PF00017 ; PF00018 More >>	26.923 (70/260)	1.53E-19
Erbb4 tyrosine kinase receptor (Erbb-4)	PF00757 ; PF14843 ; PF07714 ; PF01030 More >>	29.612 (61/206)	1.97E-19
Janus kinase 3 (JAK-3)	PF18379 ; PF18377 ; PF17887 ; PF07714 More >>	27.138 (73/269)	7.80E-19
Janus kinase 1 (JAK-1)	PF18379 ; PF18377 ; PF17887 ; PF07714 More >>	29.310 (68/232)	8.91E-19
Hematopoietic cell kinase (HCK)	PF07714 ; PF00017 ; PF00018 More >>	25.000 (64/256)	1.26E-18
Insulin-like growth factor I receptor (IGF1R)	PF00757 ; PF07714 ; PF01030 More >>	25.461 (69/271)	1.74E-18
Testis-specific kinase 1 (TESK1)	PF07714	28.641 (59/206)	2.48E-18
Fibroblast growth factor receptor 4 (FGFR4)	PF07679 ; PF13927 ; PF07714 More >>	27.586 (80/290)	2.49E-18
Non-receptor tyrosine-protein kinase TNK1 (TNK1)	PF07714	28.986 (60/207)	3.02E-18
Yes tyrosine kinase (YES)	PF07714 ; PF00017 ; PF00018 More >>	26.217 (70/267)	4.60E-18
Proto-oncogene c-Met (MET)	PF07714 ; PF01437 ; PF01403 ; PF01833 More >>	28.033 (67/239)	4.89E-18
Erbb3 tyrosine kinase receptor (Erbb-3)	PF00757 ; PF14843 ; PF07714 ; PF01030 More >>	28.269 (80/283)	5.12E-18
Testis-specific kinase 2 (TESK2)	PF07714	28.000 (56/200)	6.13E-18
Tyrosine-protein kinase FRK (FRK)	PF07714 ; PF00017 ; PF00018 More >>	27.027 (70/259)	6.22E-18
Focal adhesion kinase 2 (PTK2B)	PF00373 ; PF18038 ; PF03623 ; PF07714 More >>	28.462 (74/260)	7.32E-18
Proto-oncogene c-Src (SRC)	PF07714 ; PF00017 ; PF00018 More >>	26.217 (70/267)	7.82E-18
Fibroblast growth factor receptor 2 (FGFR2)	PF07679 ; PF13927 ; PF07714 More >>	29.258 (67/229)	8.49E-18
Kinase suppressor of Ras-1 (KSR1)	PF07714 ; PF13543 ; PF20406 More >>	24.436 (65/266)	1.11E-17
LCK tyrosine protein kinase (LCK)	PF07714 ; PF00017 ; PF00018 More >>	25.781 (66/256)	1.89E-17
Insulin receptor (INSR)	PF00757 ; PF17870 ; PF07714 ; PF01030 More >>	25.279 (68/269)	2.09E-17
Tyrosine-protein kinase TXK (TXK)	PF07714 ; PF00017 ; PF00018 More >>	28.641 (59/206)	2.43E-17
Receptor-interacting protein 1 (RIPK1)	PF00531 ; PF07714 ; PF12721 More >>	24.904 (65/261)	2.66E-17
Fibroblast growth factor receptor 1 (FGFR1)	PF07679 ; PF00047 ; PF07714 More >>	28.444 (64/225)	2.69E-17
Tyrosine-protein kinase BMX (BMX)	PF00779 ; PF00169 ; PF07714 ; PF00017 More >>	26.978 (75/278)	3.21E-17
Proto-oncogene c-Ros (ROS1)	PF00041 ; PF07714	26.408 (75/284)	4.43E-17
Ephrin type-B receptor 1 (EPHB1)	PF14575 ; PF01404 ; PF00041 ; PF07714 ; PF00536 More >>	26.336 (69/262)	5.18E-17
Serine/threonine-protein kinase TNNI3K (TNNI3K)	PF12796 ; PF13637 ; PF07714 More >>	27.230 (58/213)	5.30E-17
Macrophage-stimulating protein receptor (RON)	PF07714 ; PF01403 ; PF01833 More >>	24.566 (85/346)	5.90E-17
Angiopoietin 1 receptor (TEK)	PF00041 ; PF10430 ; PF07714 More >>	24.088 (66/274)	6.54E-17
Insulin receptor-related protein (INSRR)	PF00757 ; PF07714 ; PF01030 More >>	30.332 (64/211)	6.91E-17
Fyn tyrosine protein kinase (FYN)	PF07714 ; PF00017 ; PF00018 More >>	26.592 (71/267)	1.87E-16
ALK tyrosine kinase receptor (ALK)	PF12810 ; PF00629 ; PF07714 More >>	27.197 (65/239)	1.87E-16
Tyrosine-protein kinase Srms (SRMS)	PF07714 ; PF00017	28.405 (73/257)	2.38E-16
Focal adhesion kinase 1 (FAK)	PF00373 ; PF18038 ; PF03623 ; PF07714 More >>	27.413 (71/259)	3.34E-16
Muscle-specific kinase receptor (MUSK)	PF01392 ; PF07679 ; PF13927 ; PF07714 More >>	23.711 (69/291)	4.05E-16
Neurotrophic tyrosine kinase ROR1 (ROR1)	PF01392 ; PF07679 ; PF00051 ; PF07714 More >>	26.291 (56/213)	4.07E-16
Epidermal growth factor receptor (EGFR)	PF00757 ; PF14843 ; PF07714 ; PF01030 More >>	29.268 (60/205)	5.63E-16
Fibroblast growth factor receptor 3 (FGFR3)	PF07679 ; PF13927 ; PF07714 More >>	26.259 (73/278)	6.33E-16
TYRO3 tyrosine kinase receptor (TYRO3)	PF00041 ; PF07679 ; PF07714 More >>	25.497 (77/302)	7.27E-16
Ephrin type-B receptor 2 (EPHB2)	PF14575 ; PF01404 ; PF07699 ; PF00041 ; PF07714 ; PF00536 More >>	25.856 (68/263)	1.20E-15
Erbb2 tyrosine kinase receptor (HER2)	PF00757 ; PF14843 ; PF07714 ; PF01030 More >>	31.068 (64/206)	1.37E-15
Tyrosine-protein kinase Mer (MERTK)	PF00041 ; PF00047 ; PF07714 More >>	25.965 (74/285)	1.52E-15
Tie-1 tyrosine kinase receptor (TIE1)	PF00041 ; PF00047 ; PF07714 More >>	24.908 (68/273)	1.96E-15
Leukocyte receptor tyrosine kinase (LTK)	PF12810 ; PF07714	29.048 (61/210)	2.05E-15
Tyrosine-protein kinase BTK (ATK)	PF00779 ; PF00169 ; PF07714 ; PF00017 ; PF00018 More >>	25.287 (66/261)	2.52E-15
Titin (TTN)		27.037 (73/270)	2.85E-15
Activated CDC42 kinase 1 (ACK-1)	PF09027 ; PF11555 ; PF07714 ; PF14604 More >>	25.000 (65/260)	3.57E-15
Megakaryocyte-associated tyrosine-protein kinase (MATK)	PF07714 ; PF00017 ; PF00018 More >>	26.887 (57/212)	4.49E-15
BDNF/NT-3 growth factors receptor (TrkB)	PF07679 ; PF13855 ; PF16920 ; PF01462 ; PF07714 More >>	26.119 (70/268)	4.89E-15
Tyrosine-protein kinase CSK (CSK)	PF07714 ; PF00017 ; PF00018 More >>	25.869 (67/259)	5.16E-15
Tyrosine-protein kinase Fgr (FGR)	PF07714 ; PF00017 ; PF00018 More >>	27.509 (74/269)	5.97E-15
Tyrosine-protein kinase UFO (AXL)	PF00041 ; PF13927 ; PF07714 More >>	26.126 (58/222)	8.17E-15
Ephrin type-B receptor 3 (EPHB3)	PF14575 ; PF01404 ; PF07699 ; PF00041 ; PF07714 ; PF00536 More >>	26.538 (69/260)	9.22E-15
Tyrosine-protein kinase ZAP-70 (ZAP-70)	PF07714 ; PF00017	26.728 (58/217)	1.17E-14
Ephrin type-B receptor 4 (EPHB4)	PF14575 ; PF01404 ; PF07699 ; PF00041 ; PF07714 ; PF00536 More >>	26.515 (70/264)	1.25E-14
Tyrosine-protein kinase SYK (SYK)	PF07714 ; PF00017	26.667 (68/255)	1.85E-14
Tropomyosin-related kinase A (TrkA)	PF13855 ; PF16920 ; PF07714 ; PF18613 More >>	25.725 (71/276)	2.61E-14
Ephrin type-A receptor 3 (EPHA3)	PF14575 ; PF01404 ; PF07699 ; PF00041 ; PF07714 ; PF07647 More >>	24.335 (64/263)	4.51E-14
Proto-oncogene c-Ret (RET)	PF00028 ; PF07714 ; PF17756 ; PF17812 ; PF17813 More >>	25.714 (72/280)	4.73E-14
Platelet-derived growth factor receptor alpha (PDGFRA)	PF07679 ; PF07714	29.091 (48/165)	1.13E-13
NT-3 growth factor receptor (TrkC)	PF07679 ; PF00047 ; PF13855 ; PF16920 ; PF01462 ; PF07714 More >>	25.260 (73/289)	1.28E-13
Serine/threonine-protein kinase LMTK1 (AATK)	PF07714	25.604 (53/207)	1.47E-13
Ephrin type-A receptor 2 (EPHA2)	PF14575 ; PF01404 ; PF00041 ; PF07714 ; PF00536 More >>	23.529 (60/255)	1.53E-13
Ephrin type-A receptor 7 (EPHA7)	PF14575 ; PF01404 ; PF07699 ; PF00041 ; PF07714 ; PF00536 More >>	24.335 (64/263)	2.82E-13
B lymphocyte kinase (BLK)	PF07714 ; PF00017 ; PF00018 More >>	24.806 (64/258)	3.59E-13
Ephrin type-A receptor 1 (EPHA1)	PF14575 ; PF01404 ; PF07699 ; PF00041 ; PF07714 ; PF00536 More >>	24.904 (65/261)	5.99E-13
Tyrosine-protein kinase Kit (KIT)	PF00047 ; PF07714	28.662 (45/157)	1.02E-12
Platelet-derived growth factor receptor beta (PDGFRB)	PF07679 ; PF00047 ; PF13927 ; PF07714 More >>	28.916 (48/166)	1.79E-12
Discoidin domain-containing receptor 2 (DDR2)	PF00754 ; PF07714	24.648 (70/284)	2.57E-12
Ephrin type-A receptor 4 (EPHA4)	PF14575 ; PF01404 ; PF00041 ; PF07714 ; PF07647 More >>	24.521 (64/261)	3.96E-12
Serine/threonine-protein kinase LMTK3 (LMTK3)	PF07714	26.852 (58/216)	1.09E-11
Ephrin type-A receptor 8 (EPHA8)	PF14575 ; PF01404 ; PF00041 ; PF07714 ; PF00536 More >>	24.521 (64/261)	1.23E-11
Fms-like tyrosine kinase 3 (FLT-3)	PF00047 ; PF07714	29.221 (45/154)	1.84E-11
Vascular endothelial growth factor receptor 1 (FLT-1)	PF07679 ; PF00047 ; PF13927 ; PF07714 ; PF17988 More >>	27.564 (43/156)	1.90E-11
Inactive tyrosine-protein kinase 7 (PTK7)	PF07679 ; PF13927 ; PF07714 More >>	22.222 (60/270)	5.03E-11
Epithelial discoidin domain receptor 1 (DDR1)	PF00754 ; PF07714	22.819 (68/298)	5.19E-11
Receptor-interacting serine/threonine-protein kinase 2 (RIPK2)	PF00619 ; PF07714	25.185 (68/270)	5.27E-11
Macrophage colony-stimulating factor 1 receptor (CSF1R)	PF00047 ; PF13927 ; PF07714 More >>	27.950 (45/161)	5.56E-11
Ephrin type-A receptor 5 (EPHA5)	PF14575 ; PF01404 ; PF00041 ; PF07714 ; PF00536 More >>	23.622 (60/254)	5.60E-11
Neurotrophic tyrosine kinase ROR2 (ROR2)	PF01392 ; PF07679 ; PF00051 ; PF07714 More >>	25.352 (54/213)	9.53E-11
Ankyrin repeat and protein kinase domain-containing protein 1 (ANKK1)	PF12796 ; PF13637 ; PF07714 More >>	24.242 (56/231)	1.74E-10
Vascular endothelial growth factor receptor 3 (FLT-4)	PF07679 ; PF13927 ; PF07714 ; PF17988 More >>	22.388 (60/268)	2.65E-10
Guanylyl cyclase C (GUCY2C)	PF00211 ; PF07714	23.636 (52/220)	3.78E-10
Dual serine/threonine and tyrosine protein kinase (DSTYK)	PF07714	25.564 (68/266)	7.02E-10
Vascular endothelial growth factor receptor 2 (KDR)	PF07679 ; PF13927 ; PF07714 ; PF17988 More >>	25.767 (42/163)	9.40E-10
Ephrin type-A receptor 10 (EPHA10)	PF14575 ; PF01404 ; PF00041 ; PF07714 ; PF00536 More >>	23.774 (63/265)	3.41E-09
Integrin-linked protein kinase 1 (ILK)	PF12796 ; PF07714	22.672 (56/247)	5.40E-09
Tyrosine-protein kinase RYK (RYK)	PF07714 ; PF02019	22.711 (62/273)	1.17E-08
Atrial natriuretic peptide receptor A (NPR1)	PF01094 ; PF00211 ; PF07714 More >>	23.077 (63/273)	2.41E-08
Ephrin type-A receptor 6 (EPHA6)	PF14575 ; PF01404 ; PF07699 ; PF00041 ; PF07714 ; PF00536 More >>	24.742 (48/194)	2.56E-08
Tyrosine-protein kinase STYK1 (STYK1)	PF07714	26.702 (51/191)	1.31E-07
Serine/threonine-protein kinase LMTK2 (LMTK2)	PF07714	21.531 (45/209)	2.21E-07
Activin receptor type-1C (ACVR1C)	PF01064 ; PF07714 ; PF08515 More >>	25.000 (57/228)	3.96E-07
Atrial natriuretic peptide receptor B (NPR2)	PF01094 ; PF00211 ; PF07714 More >>	23.316 (45/193)	4.24E-07
Mixed lineage kinase domain-like protein (MLKL)	PF07714	23.423 (52/222)	9.86E-07
Nuclear receptor-binding protein (NRBP1)	PF07714	23.171 (57/246)	1.44E-06
Ephrin type-B receptor 6 (EPHB6)	PF14575 ; PF01404 ; PF07699 ; PF00041 ; PF07714 ; PF07647 More >>	23.923 (50/209)	1.45E-06
TGF-beta receptor type II (TGFBR2)	PF08917 ; PF07714	25.417 (61/240)	6.13E-06
Activin receptor-like kinase 2 (ALK-2)	PF01064 ; PF07714 ; PF08515 More >>	24.000 (54/225)	6.96E-06
Activin receptor-like kinase-1 (ACVRL1)	PF07714 ; PF08515	25.339 (56/221)	7.03E-06
Inactive serine/threonine-protein kinase TEX14 (TEX14)	PF12796 ; PF07714	23.333 (49/210)	1.15E-05
Bone morphogenetic protein receptor type-1A (BMPR1A)	PF01064 ; PF07714 ; PF08515 More >>	23.611 (51/216)	2.89E-05
Retinal guanylyl cyclase 2 (GUCY2F)	PF01094 ; PF00211 ; PF07701 ; PF07714 More >>	23.500 (47/200)	5.52E-05
Soluble guanylyl cyclase (GUCY2D)	PF01094 ; PF00211 ; PF07701 ; PF07714 More >>	22.051 (43/195)	7.66E-04
Bone morphogenetic protein receptor type-1B (BMPR1B)	PF01064 ; PF07714 ; PF08515 More >>	22.222 (48/216)	3.00E-03
Click to Show/Hide the Information of Human Similarity Proteins

References

Top

REF 1

Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.

REF 2

ClinicalTrials.gov (NCT03065010) Study of BCD-115 in Women With ER(+) HER2(-) Local Advanced and Metastatic Breast Cancer. U.S. National Institutes of Health.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.

Prof. Feng ZHU

Prof. Yuzong CHEN